COVID-19 vaccine study that was blocked from CDC journal is published elsewhere

A study examining the effectiveness of the COVID-19 vaccine has been published in a peer-reviewed journal after initially being blocked from appearing in the Centers for Disease Control and Prevention (CDC)'s official publication. The research, now published in *JAMA Network Open*, found that the vaccine was approximately 55% effective in preventing hospitalizations due to COVID-19 and reduced visits to emergency departments and urgent care clinics by 50%. These findings align with previous studies showing that vaccines significantly reduce the risk of severe illness and hospitalization. However, the controversy surrounding its initial rejection by the CDC has drawn significant public and academic interest.

The study was originally slated for publication in the CDC’s *Morbidity and Mortality Weekly Report* (MMWR), the agency’s primary scientific journal. According to Althea Grant-Lenzy, the CDC’s chief science officer, the paper had passed the internal scientific review process conducted by the Office of Science. However, it was later flagged by Jay Bhattacharya, the acting director of the CDC. His concerns centered on the study's methodology, specifically the "test-negative design" approach. This method involves comparing the vaccination status of individuals who tested positive for COVID-19 with those who tested negative for the virus but presented with similar respiratory symptoms. The goal is to estimate vaccine effectiveness based on these comparisons.

Bhattacharya argued that the test-negative design relied on assumptions that could lead to biased results. Factors such as prior infections and variations in patient behavior might skew outcomes, he claimed. Critics of his position, however, pointed out that this methodology has been widely used in public health research for decades and has appeared in reputable journals like *Pediatrics* and the *New England Journal of Medicine*. They emphasized that while no study design is flawless, the test-negative approach remains one of the most practical ways to assess vaccine performance in real-time.

The debate over the study’s validity intensified during a recent CDC forum where experts discussed the merits and drawbacks of the test-negative design. Natalie Dean, a biostatistics expert from Emory University, highlighted the importance of continuing to monitor and publish vaccine effectiveness, especially given the ongoing evolution of the virus and immune responses. She underscored the need for transparency in understanding how vaccines perform under varying conditions.

Martin Kulldorff, a Swedish-born biostatistician and co-author of the controversial Great Barrington Declaration, also participated in the discussion. Kulldorff criticized the use of the test-negative design, suggesting that it should exclude individuals with different underlying conditions. He further questioned the reliance on shorter-term studies to evaluate vaccine efficacy, prompting a strong reaction from the audience. One attendee retorted, “We were in a pandemic! That’s why!”

Despite the controversy, the study was ultimately published in *JAMA Network Open*, allowing the findings to reach a broader audience. The authors acknowledged potential limitations of the test-negative design, noting that individuals who seek medical care may differ from the general population in terms of health behaviors and access to healthcare. Additionally, the study only included individuals who had sought medical attention, potentially excluding those who remained asymptomatic or were never hospitalized.

The publication of the study has reignited discussions about the role of political influences in scientific publishing within federal health agencies. Jay Bhattacharya's decision to block the paper initially raised concerns among public health professionals about the integrity of the CDC's scientific processes. Some viewed the move as an attempt to suppress evidence supporting vaccine effectiveness, particularly in light of the broader anti-vaccine sentiments associated with figures like Health and Human Services Secretary Robert F. Kennedy Jr., who has previously expressed skepticism about the safety of the vaccines.

Moving forward, the publication of the study in an independent journal ensures that the findings will remain accessible to both the scientific community and the public. While debates about the methodology will likely persist, the study contributes valuable insights into the real-world impact of vaccines. As new variants of the virus emerge and vaccination strategies evolve, continued monitoring of vaccine effectiveness will remain crucial for public health policy and individual decision-making.